Literature DB >> 24671939

Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding.

Joshua T Schiffer1, Bryan T Mayer, Youyi Fong, David A Swan, Anna Wald.   

Abstract

Herpes simplex virus (HSV)-2 is periodically shed in the human genital tract, most often asymptomatically, and most sexual transmissions occur during asymptomatic shedding. It would be helpful to identify a genital viral load threshold necessary for transmission, as clinical interventions that maintain viral quantity below this level would be of high utility. However, because viral expansion, decay and re-expansion kinetics are extremely rapid during shedding episodes, it is impossible to directly measure genital viral load at the time of sexual activity. We developed a mathematical model based on reproducing shedding patterns in transmitting partners, and median number of sex acts prior to transmission in discordant couples, to estimate infectivity of single viral particles in the negative partner's genital tract. We then inferred probability estimates for transmission at different levels of genital tract viral load in the transmitting partner. We predict that transmission is unlikely at viral loads less than 10(4) HSV DNA copies. Moreover, most transmissions occur during prolonged episodes with high viral copy numbers. Many shedding episodes that result in transmission do not reach the threshold of clinical detection, because the ulcer remains very small, highlighting one reason why HSV-2 spreads so effectively within populations.

Entities:  

Keywords:  mathematical model; transmission; virology

Mesh:

Year:  2014        PMID: 24671939      PMCID: PMC4006256          DOI: 10.1098/rsif.2014.0160

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  37 in total

1.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.

Authors:  Anna Wald; Katherine Link
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

2.  The relationship between condom use and herpes simplex virus acquisition.

Authors:  Anna Wald; Andria G M Langenberg; Elizabeth Krantz; John M Douglas; H Hunter Handsfield; Richard P DiCarlo; Adaora A Adimora; Allen E Izu; Rhoda Ashley Morrow; Lawrence Corey
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

3.  Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women.

Authors:  A Wald; A G Langenberg; K Link; A E Izu; R Ashley; T Warren; S Tyring; J M Douglas; L Corey
Journal:  JAMA       Date:  2001-06-27       Impact factor: 56.272

4.  Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.

Authors:  Joshua T Schiffer; Laith Abu-Raddad; Karen E Mark; Jia Zhu; Stacy Selke; David M Koelle; Anna Wald; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

5.  Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.

Authors:  Sunitha Tata; Christine Johnston; Meei-Li Huang; Stacy Selke; Amalia Magaret; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

6.  Genital shedding of herpes simplex virus among men.

Authors:  Anna Wald; Judith Zeh; Stacy Selke; Terri Warren; Rhoda Ashley; Lawrence Corey
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

7.  Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes.

Authors:  S E Straus; L Corey; R L Burke; B Savarese; G Barnum; P R Krause; R G Kost; J L Meier; R Sekulovich; S F Adair
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

8.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Authors:  Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

9.  Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.

Authors:  Jia Zhu; David M Koelle; Jianhong Cao; Julio Vazquez; Meei Li Huang; Florian Hladik; Anna Wald; Lawrence Corey
Journal:  J Exp Med       Date:  2007-02-26       Impact factor: 14.307

10.  Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition.

Authors:  Jia Zhu; Florian Hladik; Amanda Woodward; Alexis Klock; Tao Peng; Christine Johnston; Michael Remington; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

View more
  32 in total

1.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

Review 2.  Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Authors:  Joshua T Schiffer; Sami L Gottlieb
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

3.  Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.

Authors:  Elfriede Agyemang; Amalia S Magaret; Stacy Selke; Christine Johnston; Larry Corey; Anna Wald
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

4.  Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition.

Authors:  Meena Ramchandani; Stacy Selke; Amalia Magaret; Gail Barnum; Meei-Li Wu Huang; Lawrence Corey; Anna Wald
Journal:  Sex Transm Infect       Date:  2017-11-25       Impact factor: 3.519

Review 5.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

6.  Herpes Simplex [corrected] Virus Type 2 Shedding From Male Circumcision Wounds in Rakai, Uganda.

Authors:  Mary K Grabowski; Godfrey Kigozi; Ronald H Gray; Benjamin Armour; Jordyn Manucci; David Serwadda; Andrew D Redd; Fred Nalugoda; Eshan U Patel; Maria J Wawer; Thomas C Quinn; Aaron A R Tobian
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

7.  Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells.

Authors:  Pavitra Roychoudhury; David A Swan; Elizabeth Duke; Lawrence Corey; Jia Zhu; Veronica Davé; Laura Richert Spuhler; Jennifer M Lund; Martin Prlic; Joshua T Schiffer
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 8.  A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation.

Authors:  Peter G E Kennedy; Joel Rovnak; Hussain Badani; Randall J Cohrs
Journal:  J Gen Virol       Date:  2015-03-20       Impact factor: 3.891

9.  Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.

Authors:  Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

10.  Transcriptional Analysis of the Guinea Pig Mucosal Immune Response to Intravaginal Infection with Herpes Simplex Virus Type 2.

Authors:  Ronald L Veselenak; Gregg N Milligan; Aaron L Miller; Richard B Pyles; Nigel Bourne
Journal:  Virology       Date:  2018-03-28       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.